Seattle's lead drug Brentuximab performs in Hodgkin's lymphoma trial

29 September 2010

Seattle Genetics of the USA has been lifted by positive data from a pivotal trial of lymphoma drug brentuximab vedotin (SGN-35), its lead product candidate.

The study in 102 relapsed or refractory Hodgkin lymphoma patients found that 75% of those treated with the drug achieved an objective response, with a median response time of six months. There were no surprises on the safety profile either, said Seattle Genetics in a statement, with adverse events in line with those seen in earlier studies.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



Companies featured in this story

More ones to watch >






Company Spotlight



More Features in Pharmaceutical